A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Cancer - Cervix Uteri,
Cancer - Corpus Uteri,
Cancer - Other Female Genital,
Cancer - Ovary
For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email firstname.lastname@example.org.